{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Ocuphire Pharma, Inc.
Ocuphire Pharma Hits New 52-Week High of $2.30, Reflecting Strong Growth
Ocuphire Pharma, Inc. achieved a new 52-week high of USD 2.30 on October 31, 2025, reflecting a strong performance with a one-year gain of 35.29%. The company, categorized as a microcap stock, operates in the Pharmaceuticals & Biotechnology industry and currently faces financial challenges.
Ocuphire Pharma Hits New 52-Week High of $2.16, Marking Significant Growth
Ocuphire Pharma, Inc. achieved a new 52-week high of USD 2.16 on October 7, 2025, significantly up from its 52-week low of USD 0.65. With a market cap of USD 84 million, the company operates at a loss and has a premium price-to-book ratio, reflecting its market dynamics.
Ocuphire Pharma Hits New 52-Week High of $2.11, Reflecting Strong Growth
Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 2.11, significantly up from its low of USD 0.65. With a market cap of USD 84 million, the company faces challenges, including a negative return on equity and a high price-to-book ratio, reflecting its competitive industry landscape.
Ocuphire Pharma Hits New 52-Week High of $1.92, Signaling Growth Potential
Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.92, significantly up from its low of USD 0.65, reflecting a year-over-year performance of 10.59%. The company, with a market cap of USD 84 million, faces financial challenges, including a loss-making position and a high debt-to-equity ratio.
Ocuphire Pharma Hits New 52-Week High of $1.83
Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.83, significantly up from its low of USD 0.65. The company, with a market cap of USD 84 million, faces challenges reflected in its negative return on equity and high price-to-book ratio, amid a competitive market landscape.
Ocuphire Pharma Hits New 52-Week High of $1.76, Signaling Growth
Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.76, significantly up from its low of USD 0.65. With a market capitalization of approximately USD 84 million, the company remains in the microcap category, despite ongoing financial challenges and a modest one-year performance compared to broader market indices.
Is Ocuphire Pharma, Inc. technically bullish or bearish?
As of September 2, 2025, Ocuphire Pharma, Inc. has a bullish technical trend with strong indicators, outperforming the S&P 500 in the short term but underperforming over the longer term.
Is Ocuphire Pharma, Inc. overvalued or undervalued?
As of March 8, 2024, Ocuphire Pharma, Inc. is considered risky due to its overvaluation, highlighted by a Price to Book Value of 12.23, negative earnings, a staggering ROE of -660.22%, and a troubling long-term decline of -83.87% over five years, despite recent short-term stock performance.
Is Ocuphire Pharma, Inc. overvalued or undervalued?
As of March 8, 2024, Ocuphire Pharma, Inc. is considered overvalued and risky due to its negative financial metrics, including a P/E ratio and ROE of -660.22%, and has significantly underperformed the S&P 500 with a year-to-date decline of 23.85%.
Is Ocuphire Pharma, Inc. technically bullish or bearish?
As of June 11, 2025, Ocuphire Pharma, Inc. is in a mildly bearish trend, supported by bearish daily moving averages and Bollinger Bands, despite some mixed signals from the MACD and KST, while significantly underperforming the S&P 500.
What does Ocuphire Pharma, Inc. do?
Ocuphire Pharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $4 million and a net loss of $8 million as of March 2025, with a market cap of $55.10 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -660.22%.
How big is Ocuphire Pharma, Inc.?
As of Jun 18, Ocuphire Pharma, Inc. has a market capitalization of 55.10 million, classifying it as a Micro Cap company, with net sales of 13.65 million and a net profit of -58.61 million over the latest four quarters. The company reported shareholder's funds of 6.72 million and total assets of 36.89 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
